Evaluate the Pharmacokinetics of BAT2606 Injection in Healthy Chinese Male Subjects

NCT05576454 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

207

Enrollment

INDUSTRY

Sponsor class

Conditions

Severe Asthma

Interventions

DRUG: Mepolizumab Injection (BAT2606 Injection)
DRUG: Mepolizumab Injection (EU-licensed Nucala)
DRUG: Mepolizumab Injection (US-licensed Nucala)

Sponsor

Bio-Thera Solutions